Short interest for Axsome Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Axsome Therapeutics's stock. Short interest data is updated every two weeks.

Axsome Therapeutics Stock (NASDAQ:AXSM), Short Interest Report

Axsome Therapeutics

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

News

Price Target

Small Cap

Markets

Analyst Ratings

Trading Ideas

ARGX

AXSM

MSFT

STOK

TSLA

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday

laboratory-563423_1280

Biotech

Equities

Large Cap

Health Care

General

Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant reductions in cataplexy attacks, improved daytime wakefulness, and cognitive function.

What&#39;s Going On Neurology-Focused Axsome Therapeutics&#39; Stock On Monday?

brain-3168269_1920

Earnings

Movers

Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth.

Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones

Axsome Therapeutics Inc

<p>Mizuho  analyst Graig Suvannavejh   maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and lowers the price target from $109 to $106.</p>


Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $106

<p>Citigroup  analyst David Hoang   maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and lowers the price target from $127 to $125.</p>


Citigroup Maintains Buy on Axsome Therapeutics, Lowers Price Target to $125

<p>Baird  analyst Joel Beatty   maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $108 to $112.</p>


Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $112

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $190 price target.</p>


Reiteration

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $190 Price Target

<p>Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) reported quarterly losses of $(1.44) per share which missed the analyst consensus estimate of $(1.21) by 19.01 percent.  The company reported quarterly sales of $74.999 million which beat the analyst consensus estimate of $73.295 million by 2.32 percent.  This is a 20.70 percent decrease over sales of $94.576 million the same period last year.</p>


Earnings Beats

Earnings Misses

Axsome Therapeutics Q1 2024 GAAP EPS $(1.44) Misses $(1.21) Estimate, Sales $74.999M Beat $73.295M Estimate

<p>Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $131.89, a high estimate of $190.00, and a low estimate of $103.00. This current average has increased by 6.52% from the previous average price target of $123.82. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399281_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Axsome Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$109.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$108.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$123.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$108.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$111.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Axsome Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Axsome Therapeutics analyst ratings.</strong></a></p>
<h2>Get to Know Axsome Therapeutics Better</h2>
<p>Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.</p>
<h3>Axsome Therapeutics: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Axsome Therapeutics showcased positive performance, achieving a revenue growth rate of <strong>193.5%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-137.92%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Axsome Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-42.85%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Axsome Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-16.59%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Axsome Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.98</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights

<p>Morgan Stanley  analyst Vikram Purohit   upgrades Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) from Equal-Weight to Overweight and raises the price target from $90 to $115.</p>


Upgrades

Morgan Stanley Upgrades Axsome Therapeutics to Overweight, Raises Price Target to $115

<p>Providing a diverse range of perspectives from bullish to bearish, 20 analysts have published ratings on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) in the last three months.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $130.3, a high estimate of $190.00, and a low estimate of $103.00. Observing a 5.23% increase, the current average has risen from the previous average price target of $123.82. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1712764815_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Axsome Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$109.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$108.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$123.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$108.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$111.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$126.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$108.00</td>
<td>-</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Axsome Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Axsome Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Axsome Therapeutics analyst ratings.</strong></a></p>
<h2>About Axsome Therapeutics</h2>
<p>Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.</p>
<h3>Axsome Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Axsome Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>193.5%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Axsome Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-137.92%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Axsome Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-42.85%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-16.59%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Axsome Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.98</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings For Axsome Therapeutics

<p>Cantor Fitzgerald  analyst Charles Duncan   reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Overweight and maintains $107 price target.</p>


Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $107 Price Target

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $190 price target.</p>


HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Maintains $190 Price Target

Axsome Therapeutics Has Initiated ENGAGE Phase 3 Trial Of Solriamfetol, An Investigational Treatment For Binge Eating Disorder In Adults

<p>Mizuho  analyst Graig Suvannavejh   maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and raises the price target from $108 to $109.</p>


Mizuho Maintains Buy on Axsome Therapeutics, Raises Price Target to $109

<p>Truist Securities  analyst Joon Lee   maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $150 price target.</p>


Truist Securities Maintains Buy on Axsome Therapeutics, Maintains $150 Price Target

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.</p>
<ul>
<li>Keybanc boosted the price target for <strong> Worthington Steel, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ws#NYSE">WS</a>) from $31 to $39. Keybanc analyst Philip Gibbs maintained an Overweight rating. Worthington Steel shares fell 2.9% to close at $34.34 on Monday. <a href="https://www.benzinga.com/quote/WS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group boosted the price target for <strong> PVH Corp. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pvh#NYSE">PVH</a>) from $122 to $155. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. PVH shares gained 0.3% to close at $134.77 on Monday. <a href="https://www.benzinga.com/quote/PVH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley increased <strong> Seagate Technology Holdings plc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stx#NASDAQ">STX</a>) price target from $73 to $115. Morgan Stanley analyst Erik Woodring upgraded the stock from Equal-Weight to Overweight. Seagate shares fell 0.9% to close at $88.21 on Monday. <a href="https://www.benzinga.com/quote/STX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted the price target for <strong> Stoke Therapeutics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stok#NASDAQ">STOK</a>) from $14 to $22. Needham analyst Joseph Stringer maintained a Buy rating. Stoke Therapeutics shares gained 3.2% to close at $6.50 on Monday. <a href="https://www.benzinga.com/quote/STOK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised <strong> Axsome Therapeutics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axsm#NASDAQ">AXSM</a>) price target from $180 to $190. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Axsome Therapeutics shares fell 4.1% to close at $77.35 on Monday. <a href="https://www.benzinga.com/quote/AXSM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush boosted the price target for <strong> Microsoft Corporation </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) from $475 to $500. Wedbush analyst Daniel Ives maintained an Outperform rating. Microsoft shares fell 1.4% to close at $422.86 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Bernstein cut <strong> Tesla, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) price target from $150 to $120. Bernstein analyst Toni Sacconaghi maintained an Underperform rating. Tesla shares gained 1.1% to close at $172.63 on Monday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo boosted <strong> The Gap, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gps#NYSE">GPS</a>) price target from $25 to $32. Wells Fargo analyst Ike Boruchow maintained an Overweight rating. Gap shares fell 0.6% to close at $27.91 on Monday. <a href="https://www.benzinga.com/quote/GPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein raised <strong> Chipotle Mexican Grill, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cmg#NYSE">CMG</a>) price target from $2,800 to $3,200. Bernstein analyst Danilo Gargiulo maintained an Outperform rating. Chipotle shares rose 0.7% to close at $2,903.44 on Monday. <a href="https://www.benzinga.com/quote/CMG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Scotiabank raised <strong> argenx SE </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/argx#NASDAQ">ARGX</a>) price target from $402 to $408. Scotiabank analyst George Farmer maintained a Sector Perform rating. argenx shares fell 1.1% to close at $398.42 on Monday. <a href="https://www.benzinga.com/quote/ARGX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>&nbsp;</p>
<p>Check This Out: <a href="https://www.benzinga.com/news/earnings/24/03/37927160/mccormick-td-synnex-and-3-stocks-to-watch-heading-into-tuesday"><em> McCormick, TD SYNNEX And 3 Stocks To Watch Heading Into Tuesday </em></a></p>


<p>RBC Capital  analyst Leonid Timashev   maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $123 to $128.</p>


RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $128

<p>Citigroup  analyst David Hoang   maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and raises the price target from $125 to $127.</p>


Citigroup Maintains Buy on Axsome Therapeutics, Raises Price Target to $127

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and raises the price target from $180 to $190.</p>


HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $190

<p>Monday,&nbsp;<strong>Axsome Therapeutics Inc</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) released data from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37909539/axsome-therapeutics-announces-axs-12-achieves-primary-endpoint-in-the-symphony-phase-3-trial-in-na" rel="noreferrer noopener">in narcolepsy patients</a>.</p>
<p>Narcolepsy is a sleep disorder that makes people very drowsy during the day. People with narcolepsy find it hard to stay awake for long periods.</p>
<p>AXS-12 met the primary endpoint by demonstrating a substantial and statistically significant reduction from baseline in weekly cataplexy (sudden loss of muscle tone while a person is awake leads to weakness and a loss of voluntary muscle control) attacks compared to placebo at Week 5, with reductions of 83% for AXS-12 and 66% for placebo.&nbsp;</p>
<p>AXS-12 rapidly reduced weekly cataplexy attacks, demonstrating at Week 1 a reduction of 56% compared to a reduction of 31% for placebo.</p>
<p>Remission of cataplexy, defined as a 100% reduction from baseline, was achieved at Week 5 by 33% of AXS-12 treated patients compared to 9.5% of placebo patients (p=0.008).&nbsp;</p>
<p>Achievement of remission was rapid, being experienced at Week 2 by 24% of AXS-12 treated patients compared to 4.5% of placebo patients (p=0.008).&nbsp;</p>
<p>AXS-12 increased the percentage of cataplexy-free days per week, defined as days with zero cataplexy attacks, to 84.5% at Week 5 compared to 22.6% for placebo (p=0.014).</p>
<p>AXS-12 significantly reduced excessive daytime sleepiness (EDS) severity, compared to placebo at Week 5, with mean reductions of 1.8 points for AXS-12 compared to 0.9 points for placebo. Rapid improvement in EDS was seen as early as Week 1 compared to the placebo.&nbsp;</p>
<p>Concurrent EDS and cataplexy response was achieved at Week 5 by 57% of patients treated with AXS-12 compared to 33% of placebo patients.&nbsp;</p>
<p>A decrease in inadvertent naps was experienced by 54% of AXS-12 patients at Week 5 compared to 28% of placebo patients.</p>
<p>Improvement on the Epworth Sleepiness Scale (ESS) was numerically greater for AXS-12 than for placebo, with mean reductions from baseline of 4.7 points for AXS-12 compared to 3.4 points for placebo.&nbsp;</p>
<p>Concurrent cognitive and cataplexy response was achieved at Week 5 by 41% of patients treated with AXS-12 compared to 17% of placebo patients (p=0.016).&nbsp;</p>
<p>Improvement from baseline in the Anxiety/Depression was achieved by 55% of patients treated with AXS-12 compared to 32% of placebo patients.</p>
<p>AXS-12 was well tolerated in the trial. There were no serious adverse events in the trial.</p>
<p><strong>Price Action:</strong> AXSM shares are down 3.84% at $77.56 on the last check Monday.</p>
<p><em>Photo via Darko Stojanovic from Pixabay</em></p>


What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?

Axsome Therapeutics shares are trading higher the company's AXS-12 achieved primary endpoint in the SYMPHONY phase 3 trial in narcolepsy.

<p>AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy severity as compared to placebo.&nbsp;</p>


Axsome Therapeutics' AXS-12 (Reboxetine) Achieved The Primary Endpoint And Significantly Reduced The Frequency Of Cataplexy Attacks As Compared To Placebo In Narcolepsy Patients In SYMPHONY Phase 3 Trial

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Axsome Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/axsm-stock-quote/"><strong>AXSM</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Axsome Therapeutics reported earnings per share of -$1.00. This was above the analyst estimate for EPS of -$1.21.</li><li>The company reported revenue of $75.00 million.</li><li>This was 2.08% better than the analyst estimate for revenue of $73.47 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/axsm-stock-earnings-axsome-therapeutics-for-q1-of-2024/">AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024

Axsome Therapeutics (AXSM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Hoang ...

Buy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Market Expansion Potential

Analysts fell to the sidelines weighing in on Lyra Therapeutics (LYRA – Research Report), Bristol-Myers Squibb (BMY – Research Report) and Axsome T...

Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a pric...

Buy Rating Affirmed on Axsome Therapeutics Amid Strong Sales and Strategic Positioning

Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) and keeping the price target at ...

Buy Rating Affirmed on Axsome Therapeutics Due to Strong Auvelity Sales and Promising Alzheimer's Treatment Pipeline

In a report released on May 6, Marc Goodman from Leerink Partners reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a p...

Buy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical Trials

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report), Teleflex (TFX – Re...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Teleflex (TFX) and Axsome Therapeutics (AXSM)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cigna (CI – Research Report), Axsome Therapeutics (A...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The biotech sector holds some of the most promising and popular stocks on the market. With the promise of breakthrough treatments that generate billions of dollars annually, investors always look for the next up-and-comer. And within this popular market are stocks that are valued well below their potential.</p>



<p>These three <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> have some of the most promising treatments awaiting approval. But they aren&rsquo;t trading at a value reflective of the likely explosive future growth. Investors should take advantage of the opportunity to buy these stocks at a lower price. Then plan to hold them as massive sales and approvals send their stocks higher and higher.</p>



<p>We&rsquo;ll detail the current valuations of these stocks and the treatments that each has coming down the pipeline.</p>



<h2><strong>CRISPR Therapeutics (CRSP)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/11/crispr-theraputics-crsp-stock-1600-300x169.jpg" alt="the CRISPR Therapeutics (CRSP) logo seen displayed on a smartphone"><div>Source: rafapress / Shutterstock.com</div></div><p><strong>CRISPR Therapeutics </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/crsp-stock-quote/"><strong>CRSP</strong></a></span>) offers a relatively unique set of treatments specializing in gene editing. The company&rsquo;s best-selling treatment, Casgevy, targets transfusion-dependent beta-thalassemia and sickle cell disease. After receiving Food and Drug Administration (<strong>FDA</strong>) approval for the treatment in late February, CRISPR saw a <a href="https://www.macrotrends.net/stocks/charts/CRSP/crispr-therapeutics-ag/stock-price-history">short rise</a> but has since been on the dip.</p>



<p>Also, CRISPR&rsquo;s most recent earnings report for Q1 included news of 25 <a href="https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000059.html">authorized treatment centers</a> activated globally for Casgevy. However, the company reported a net loss of $116.6 million. The number is up from last year&rsquo;s $53.1 million. And along with a revenue miss, investors are not taking to the news lightly.&nbsp;</p>



<p>However, the sinking price creates an excellent opportunity to buy CRISPR at its lowest price in years. Increased <a href="https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2023-financial-results#:~:text=The%20increase%20in%20collaboration%20expense,the%20second%20quarter%20of%202022.">commercial and manufacturing costs</a> primarily drove the net loss following the full release of Casgevy. On the other hand, that same surge created $2,108.1 million in cash, up from last quarter&rsquo;s $1,695.7 million.</p>



<p>Indeed, CRISPR will likely bounce back from this costly quarter. Further, it will continue to climb the biotech ranks as Casgevy spreads throughout the many countries.</p>



<h2><strong>Axsome Therapeutics (AXSM)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/axsm-stock-300x169.jpg" alt="A magnifying glass zooms in on the Axsome Therapeutics, Inc. (AXSM) logo"><div>Source: Pavel Kapysh/Shutterstock.com</div></div><p>An excellent pick for biotech stocks, <strong>Axsome Therapeutics </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/axsm-stock-quote/"><strong>AXSM</strong></a></span>) has diverse and plentiful treatments coming down the pipeline soon. The company&rsquo;s most prominent drug is Auvelity, which is used to treat major depressive disorder. Auvelity promised and reached $130.1 million in sales for 2023, its <a href="https://axsometherapeuticsinc.gcs-web.com/node/11251/pdf#:~:text=Fourth%20Quarter%202023%20and%20Full%20Year%20Financial%20Highlights&amp;text=Auvelity%C2%AE%20net%20product%20sales,the%20fourth%20quarter%20of%202022.">first full year</a> on the market.</p>



<p>In its most recent earnings report for Q1 of 2024, AXSM reported a considerable <a href="https://finance.yahoo.com/news/axsome-therapeutics-inc-axsm-q1-070126412.html">boost in net product revenue</a>, which increased 160% year-over-year (<strong>YOY</strong>). The jump is mainly due to Auvelity&rsquo;s sales. But, the company has several other promising treatments in later phases of clinical trials, such as AXS-07, AXS-12 and AXS-14.&nbsp;</p>



<p>Also, Axsome Therapeutics reported a net loss of $68.4 million, which was primarily due to a significant increase in <a href="https://finance.yahoo.com/news/axsome-therapeutics-inc-axsm-q1-070126412.html">research and development expense</a>s. While some investors may be hesitant due to a slight dip in EPS, the money is going to the right place to support AXSM&rsquo;s future growth.&nbsp;</p>



<p>The company&rsquo;s future treatments target relatively common conditions, such as migraines (AXS-07) and narcolepsy (AXS-12). AXS-07 is already quite close to the end of phase 3 clinical trials and is set to submit a request for and receive <a href="https://www.clinicaltrialsarena.com/analyst-comment/aan-2024-axsome-therapeuticss-axs-07/?cf-view">FDA approval</a> next year.</p>



<p>Axsome Therapeutics may be making heavy investments right now. But the potential of the drugs coming down the pipeline is undeniable and is sure to send Axsome soaring.&nbsp;</p>



<h2><strong>Iovance Biotherapeutics (IOVA)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>Taking a unique and breakthrough approach to treating cancer, <strong>Iovance Biotherapeutics </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/iova-stock-quote/"><strong>IOVA</strong></a></span>) is one of the most anticipated biotech stocks. The company&rsquo;s TIL therapy, <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma#:~:text=On%20February%2016%2C%202024%2C%20the,antibody%2C%20and%20if%20BRAF%20V600">Amtagvi, won FDA approval</a> in February of this year. Furthermore, the stock hit its peak for this year shortly thereafter.&nbsp;</p>



<p>So far, IOVA developed Amtagvi to treat metastatic melanoma but has a handful of other therapies utilizing TILs in the pipeline. The company reported a <a href="https://ir.iovance.com/node/14246/pdf">$116.4 million net loss for Q4</a> last year but primarily burnt cash on research and development. To combat such loss in the future, though, is Iovance Biotherapeutics&rsquo; ace up its sleeve, Proleukin.</p>



<p>The company acquired the rights to Proleukin, an interleukin treatment, with full approval in early 2023. Then, it commercialized Prolelukin and is selling it on the market. For investors worried about Iovance Biotherapeutics&rsquo; ability to fund its operations, the good news is the company expects <a href="https://ir.iovance.com/node/14246/pdf">revenue from Proleukin and Amtagvi to fund all plans</a> comfortably into 2025.&nbsp;</p>



<p>While Iovance Biotherapeutics is temporarily valued lower, investors can buy this extremely promising stock. Therefore, they may have high hopes for the returns it will bring in the foreseeable future.</p>



<p><em>On the date of publication, Joel Lim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>
<div><p>Joel Lim is a finance freelance writer who writes content for several companies like LTSE and Realtor, along with financial publications, including Mises Institute and Foundation for Economic Education.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/the-3-most-undervalued-biotech-stocks-to-buy-in-may-2024/">The 3 Most Undervalued Biotech Stocks to Buy in May 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 3 Most Undervalued Biotech Stocks to Buy in May 2024

AMGN

ARQT

CRSP

IOVA

LYRA

Legal

Press Releases

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors

Axsome Therapeutics Recognizes May as Mental Health Awareness Month

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Axsome Therapeutics to Present at Upcoming Investor Conferences

AMZN

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Indivior

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly and Co

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Axsome Therapeutics Stock (NASDAQ:AXSM), Short Interest Report

People Also Watch